Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRA-523 versus placebo for itch due to atopic dermatitis
ISRCTN63487177Phase 2Recruiting
- Sponsor
- Praeventix, Inc.
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in atopic dermatitis (AD) comparing PRA-523 with Placebo (2 arms). Primary endpoint: Treatment-emergent adverse events related to PRA-523 versus vehicle. Started Apr 2026; status: recruiting.
02
Drugs
PRA-523
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on ISRCTN63487177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN63487177.